Dec 12 (Reuters) - Editas Medicine Inc :
* ANNOUNCES STRATEGIC TRANSITION TO IN VIVO GENE EDITING COMPANY WITH INTENT TO ACHIEVE HUMAN PROOF OF CONCEPT IN APPROXIMATELY TWO YEARS
* INITIATING COST SAVINGS MEASURES AND REDUCTION IN HEADCOUNT TO ALIGN WORKFORCE
* WILL ELIMINATE APPROXIMATELY 65% OF ITS WORKFORCE OVER NEXT SIX MONTHS
* INTENDS TO SHARE PRE-CLINICAL DATA AND FURTHER DEVELOPMENT TIMELINES FROM PROGRAMS IN Q1 OF 2025
* JESSICA HOPFIELD, HAS BEEN NAMED CHAIR OF BOARD, EFFECTIVE DECEMBER 31
((Reuters.Briefs@thomsonreuters.com;;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。